Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953261 · ClinicalTrials.gov registry record · Phase 2
Effect of Curcumin on Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Loma Linda University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03953261 is a Phase 2 study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 23 participants.
The verdict
NCT03953261, a Phase 2 study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous. Curcumin has been found to have anti-inflammatory effects and has been found to improve disease activity in lupus patients. In addition, subjects with rheumatoid arthritis as well as osteoarthritis have also found benefit for their disease activity.
Interventions
- DRUG Curcumin supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2022-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953261
The ClinicalTrials.gov registry entry for NCT03953261 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Curcumin supplement is the first listed.
NCT03953261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03953261 about?
NCT03953261 is a clinical study titled "Effect of Curcumin on Systemic Lupus Erythematosus". The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous. Curcumin has been found to have anti-inflammatory effects and has been found to improve disease activity in lupus patients. In addition, subject...
What is the current status of trial NCT03953261?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2019-09-01. Estimated completion is 2022-04-13.
What interventions are being tested in trial NCT03953261?
The interventions under investigation include: Curcumin supplement (DRUG).
Who is sponsoring clinical trial NCT03953261?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.